Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$8.29 USD
+0.04 (0.48%)
Updated Apr 26, 2024 03:32 PM ET
After-Market: $8.21 -0.08 (-0.97%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ONCT 8.29 +0.04(0.48%)
Will ONCT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ONCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ONCT
Oncternal Therapeutics (ONCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Oncternal Therapeutics (ONCT) Reports Q4 Loss, Tops Revenue Estimates
ONCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Zoetis (ZTS) Q4 Earnings Lag Estimates
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates
Other News for ONCT
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal announces first patient dosed in fourth cohort of study of ONCT-534
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics price target lowered by $2 at H.C. Wainwright, here's why
Buy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalysts